PMID- 28950844
OWN - NLM
STAT- MEDLINE
DCOM- 20180402
LR  - 20181202
IS  - 1472-6874 (Electronic)
IS  - 1472-6874 (Linking)
VI  - 17
IP  - 1
DP  - 2017 Sep 26
TI  - Effect of simvastatin on monocyte chemoattractant protein-1 expression in 
      endometriosis patients: a randomized controlled trial.
PG  - 89
LID - 10.1186/s12905-017-0446-3 [doi]
LID - 89
AB  - BACKGROUND: Simvastatin is a promising new drug for the treatment of 
      endometriosis. It is a cholesterol-lowering drug that acts by inhibiting HMG-CoA 
      reductase, resulting in a decrease in mevalonate, a precursor of cholesterol and 
      monocyte chemoattractant protein-1 (MCP-1). This study investigated the effect of 
      pre-operative oral simvastatin administration on MCP-1 gene expression and serum 
      MCP-1 protein levels in patients with endometriosis. METHODS: A prospective, 
      randomized, controlled study was conducted at the Reproductive Endocrinology Unit 
      of the Department of Obstetrics and Gynecology at the Faculty of Medicine 
      Ramathibodi Hospital. Forty women (mean age: 18-45 years) scheduled for 
      laparoscopic surgery who had been diagnosed with endometriosis were recruited and 
      randomly assigned to either a treatment group (20 mg/d of orally administered 
      simvastatin for 2 weeks before surgery) or an untreated control group. Serum was 
      collected before and after treatment and protein levels of MCP-1 were determined. 
      MCP-1 and CD68 transcript levels were also quantified using real-time PCR on 
      endometriotic cyst tissues. RESULTS: MCP-1 gene expression on endometriotic cyst 
      was not significantly different between the simvastatin-treated and untreated 
      groups (P = 0.99). CD68 expression was higher in the treatment group compared to 
      the control group, but this was not statistically significant (P = 0.055). Serum 
      MCP-1 levels following simvastatin treatment were higher than in samples obtained 
      before treatment (297.89 +/- 70.77 and 255.51 +/- 63.79 pg/ml, respectively) 
      (P = 0.01). CONCLUSIONS: Treatment with 20 mg/d of simvastatin for 2 weeks did 
      not reduce the expression of either the chemokine MCP-1 gene or 
      macrophage-specific genes. Cumulatively, this suggests that simvastatin is not 
      ideal for treating endometriosis because a higher dose of simvastatin 
      (40-100 mg/d) would be needed to achieve the target outcome, which would 
      significantly increase the risk of myopathy in patients. TRIAL REGISTRATION: Thai 
      Clinical Trials Registry TCTR20130627003 Registered: June 27, 2013.
FAU - Waiyaput, Wanwisa
AU  - Waiyaput W
AD  - Office of Research Academic and Innovation, Faculty of Medicine, Ramathibodi 
      Hospital, Mahidol University, Bangkok, Thailand.
FAU - Pumipichet, Somphoch
AU  - Pumipichet S
AD  - Department of Obstetrics and Gynecology, Faculty of Medicine Srinakharinwirot 
      University, Bangkok, Thailand.
FAU - Weerakiet, Sawaek
AU  - Weerakiet S
AD  - Reproductive Endocrinology and Infertility Unit, Department of Obstetrics & 
      Gynecology, Ramathibodi Hospital, Mahidol University, Rama VI Rd, Bangkok, 10400, 
      Thailand.
FAU - Rattanasiri, Sasivimol
AU  - Rattanasiri S
AD  - Section for Clinical Epidemiology and Biostatistics, Faculty of Medicine, 
      Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
FAU - Sophonsritsuk, Areepan
AU  - Sophonsritsuk A
AUID- ORCID: 0000-0002-4589-0030
AD  - Reproductive Endocrinology and Infertility Unit, Department of Obstetrics & 
      Gynecology, Ramathibodi Hospital, Mahidol University, Rama VI Rd, Bangkok, 10400, 
      Thailand. areepan.sop@mahidol.ac.th.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20170926
PL  - England
TA  - BMC Womens Health
JT  - BMC women's health
JID - 101088690
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - AGG2FN16EV (Simvastatin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Chemokine CCL2/*antagonists & inhibitors/drug effects/genetics
MH  - Endometriosis/*drug therapy
MH  - Female
MH  - Gene Expression/drug effects
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*pharmacokinetics/*therapeutic use
MH  - Middle Aged
MH  - Prospective Studies
MH  - Simvastatin/*pharmacokinetics/*therapeutic use
MH  - Young Adult
PMC - PMC5615793
OTO - NOTNLM
OT  - Endometriosis
OT  - Laparoscopy
OT  - MCP-1 gene expression
OT  - Serum MCP-1
OT  - Simvastatin
COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: The study was carried out in 
      accordance with the Declaration of Helsinki and approved by the Ethical clearance 
      Committee on human rights related to researches involving human subjects of 
      Ramathibodi hospital. (protocol number ID125531) Written informed consent was 
      obtained from all participants. CONSENT FOR PUBLICATION: Not applicable. 
      COMPETING INTERESTS: The authors declare that they have no competing interests. 
      PUBLISHER'S NOTE: Springer Nature remains neutral with regard to jurisdictional 
      claims in published maps and institutional affiliations.
EDAT- 2017/09/28 06:00
MHDA- 2018/04/03 06:00
PMCR- 2017/09/26
CRDT- 2017/09/28 06:00
PHST- 2016/05/26 00:00 [received]
PHST- 2017/09/21 00:00 [accepted]
PHST- 2017/09/28 06:00 [entrez]
PHST- 2017/09/28 06:00 [pubmed]
PHST- 2018/04/03 06:00 [medline]
PHST- 2017/09/26 00:00 [pmc-release]
AID - 10.1186/s12905-017-0446-3 [pii]
AID - 446 [pii]
AID - 10.1186/s12905-017-0446-3 [doi]
PST - epublish
SO  - BMC Womens Health. 2017 Sep 26;17(1):89. doi: 10.1186/s12905-017-0446-3.